7 completed, 2 terminated, 1 withdrawn. 10 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Terminated 2, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
Follow Leukemia, Mast-Cell: new trials by email Literature Review of Leukemia, Mast-Cell trials Research Report on Leukemia, Mast-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies BLU-263, Azacitidine - Advanced Systemic Mastocytosis | Phase 1 | Terminated | Blueprint Medicines Corporation | 9 | 2023-09-25 | 2025-04-10 |
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | GT Biopharma, Inc. | 12 | 2020-01-01 | 2022-11-10 |
| (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies Avapritinib - Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease | Phase 1 | Completed | Blueprint Medicines Corporation | 86 | 2016-03-10 | 2023-03-17 |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies DCC-2618 - Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 282 | 2015-11-01 | 2023-12-13 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer donor natural killer cell infusion - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 1 / Phase 2 | Completed | Asan Medical Center | 47 | 2009-01-01 | 2013-02-20 |
| Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer PS-341, Doxil, Velcade - Breast Cancer, Leukemia | Phase 1 / Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 107 | 2001-05-01 | 2012-05-18 |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2000-05-01 | 2020-01-21 |
| Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Edetate Calcium Disodium, Ethanol, Trimethoprim-sulfamethoxazole - Chronic Myeloproliferative Disorders, Infection | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-02-15 |
Leukemia, Myeloid, Acute (7) · Burkitt Lymphoma (6) · Intraocular Lymphoma (6) · Leukemia, Hairy Cell (6) · Leukemia, Large Granular Lymphocytic (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Leukemia, Myelomonocytic, Chronic (6) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Extranodal NK-T-Cell (6) · Lymphoma, Follicular (6) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, Large-Cell, Anaplastic (6) · Lymphoma, Mantle-Cell (6) · Mycosis Fungoides (6)
Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Leukemia, Myeloid (10) · Mastocytosis (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Mast Cell Activation Disorders (9) · Bone Marrow Diseases (8) · Disease Attributes (7) · Leukemia (7) · Neoplasms by Site (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Blood Protein Disorders (6)
Azacitidine (1) · Bortezomib (1) · Cyclosporine (1) · Edetic Acid (1) · Ethanol (1) · MK 2206 (1) · Mycophenolic Acid (1) · Pentetic Acid (1) · Peripheral Blood Stem Cell Transplantation (1) · Saline Solution (1) · Saline Solution, Hypertonic (1) · Sodium Chloride (1) · Sulfamethoxazole (1) · Sunitinib (1) · Trimethoprim (1)
Blueprint Medicines Corporation (2) · National Cancer Institute (NCI) (2) · Asan Medical Center (1) · Deciphera Pharmaceuticals, LLC (1) · Fred Hutchinson Cancer Center (1) · GT Biopharma, Inc. (1) · M.D. Anderson Cancer Center (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (8) · Canada (2) · Germany (2) · Italy (2) · Netherlands (2) · United Kingdom (2) · Belgium (1) · France (1) · Norway (1) · South Korea (1) · Spain (1)
David Maloney (1) · Elizabeth C. Dees, MD (1) · John Deeken (1) · Jorge Cortes, MD (1) · Kyoo H. Lee, MD (1) · Mark B Juckett, MD (1) · Maryam Fouladi (1) · Patrick Chaftari, MD (1) · Robert Z. Orlowski, MD, PhD (1)
PMID 18327587, PMID 22259028, PMID 24474568, PMID 32499241, PMID 32804590, PMID 34873347, PMID 35640224, PMID 35790816
2015 (1), P01CA078902 (1), P30CA015704 (1), U01CA097452 (1), U01CA121947 (1)